A small pilot study of levamisole in primary biliary cirrhosis failed to demonstrate any improvement in liver function and immunological abnormalities even in 'early' cases. This may be due to the fact that the defect in the immune system lies in its afferent arm. At present, levamisole, which is potentially toxic, cannot be recommended in conventional doses for the treatment of this disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2426569 | PMC |
| http://dx.doi.org/10.1136/pgmj.58.685.701 | DOI Listing |
Publication Analysis
Top Keywords
levamisole primary
8
primary biliary
8
biliary cirrhosis
8
clinical trial
4
trial levamisole
4
cirrhosis small
4
small pilot
4
pilot study
4
study levamisole
4
cirrhosis failed
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!